Skip to content

Sections
- Health
- Pharma
- Biotech
- Hospitals
- Politics
- In the Lab
- First Opinion
- Gut Check
- The Watchdogs
Topics
- Cancer
- Concussions
- CRISPR
- Drug Pricing
- End of Life
- Health Disparities
- Immigration
- Opioids
- Trump
- Women’s Health
- Zika
Multimedia
Popular
STAT Plus

Job Board
About Us

Newsletters
My Account
- Settings
- Log Out

Newsletters
My Account
- Settings
- Log Out

Cancer

First Opinion

My sister’s cancer might have been diagnosed sooner — if doctors could have seen beyond her weight

By Laura Fraser

Health

Q&A: FDA wants to (computer) model the way to better, data-driven clinical trials

By Meghana Keshavan

advertisement

Health

In the shadow of a nuclear plant, the U.S. government lays out an unusual mission: teach the locals to trust science

advertisement

Business

As losses mount, Soon-Shiong’s NantHealth to lay off dozens, reduce headcount by 300

By Rebecca Robbins

Health

Genetic counseling works as well over the phone as in person, study finds

By Ryan Basen — MedPage Today

Gut Check

Can a ‘liquid biopsy’ detect cancer and save lives?

By Sharon Begley

Adam's Take

Ziopharm claims FDA loves its brain cancer gene therapy, so why is the Phase 3 study taking so long to start?

By Adam Feuerstein

advertisement

In the Lab

Sea sponges have given us many promising drugs. But that could change with warmer waters

By Kate Sheridan

advertisement

First Opinion

New online navigator helps patients and doctors access experimental treatments

By June S. Wasser

Pharmalot

Pharmalittle: Merck takes a victory lap; AstraZeneca fallout continues

By Damian Garde

First Opinion

Tans — even from a new drug — aren’t the way to prevent skin cancer

By Sherry Pagoto and June K. Robinson

Pharmalot

AstraZeneca trial results are ‘damaging’ to management credibility

By Ed Silverman

Biotech

A humbling setback for an immune-revving cancer therapy underscores the many questions facing the field

By Adam Feuerstein

Pharmalot

Pharmalittle: AstraZeneca inks deal with Merck as a big cancer drug trial bombs

By Ed Silverman

Pharma

AstraZeneca lung cancer immunotherapy trial failure sends shares plunging

By Adam Feuerstein

First Opinion

Dear Sen. McCain: Here’s what I’ve learned from living with glioblastoma

By Adam Hayden

Health

Does McCain’s return to Washington carry medical risks?

By Kate Sheridan and Casey Ross

Adam's Take

Merck: Keytruda trial comes up short in head and neck cancer, but FDA approval stays

By Adam Feuerstein

Health

McCain is considered a warrior. But is that the right metaphor for his struggle with cancer?

By Bob Tedeschi

Health

87 experimental therapies for glioblastoma are in the works. Some might help McCain now

By Sharon Begley

In the Lab

One big cancer breakthrough is likely on the way to patients. Here’s what may be coming next

By Damian Garde

Health

A treatment option for McCain: an electric cap that kills brain cancer cells

By Adam Feuerstein

First Opinion

Grappling with cancers like John McCain’s glioblastoma that break all the rules

By David F. Arons

Health

What to know about Sen. John McCain’s brain cancer diagnosis

By Sharon Begley

In the Lab

Redeeming qualities for belly fat? When it’s actually the omentum, sure

By Kate Sheridan

Health

‘Are you saying I’m dying?’ Training doctors to speak frankly about death

Biotech

Database sleuths turn up a surprising new drug to test against cancer

By Meghana Keshavan

Biotech

Novartis CAR-T cancer therapy wins expert support for FDA approval

By Adam Feuerstein and Damian Garde

Health

15 percent of men regret prostate cancer treatment choices years later, study finds

By Charles Bankhead — MedPage Today

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine

Sign up for our morning rounds newsletter

Reporting from the frontiers of health and medicine

About Us
Contact Us
The STAT Team
Work at STAT
Job Board
Advertise

Privacy
Comment Policy
Terms

© 2017 STAT